QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-emergent-biosolutions-maintains-15-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 ...

 emergent-biosolutions-secures-30m-barda-contract-to-supply-cyfendus-anthrax-vaccine-by-march-2026

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modification from the Biomedical A...

 emergent-biosolutions-files-for-mixed-shelf-of-up-to-250m

 -SEC Filing

 emergent-biosolutions-narrows-fy2025-sales-guidance-from-75000m-85000m-to-76500m-83500m-vs-80000m-est

Emergent BioSolutions (NYSE:EBS) narrows FY2025 sales outlook from $750.00 million-$850.00 million to $765.00 million-$835.00 m...

 emergent-biosolutions-q2-adj-eps-016-beats-072-estimate-sales-14090m-beat-10500m-estimate

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $(...

 emergent-biosolutions-publishes-comprehensive-review-on-brincidofovir-for-mpox-in-expert-review-of-anti-infective-therapy-journal

Emergent BioSolutions Inc. (NYSE:EBS) today announced the publication of a comprehensive review article, "Brincidofovir in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION